Loading
AUTHOR INFO
Benjamin Lichtbroun
Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USAArticles List
Pharmacologic Therapies for Non-Muscle Invasive Bladder Cancer: Current and Future Treatments
Saum Ghodoussipour , Eric A. Singer , Ilana P. Goldberg , Benjamin Lichtbroun
Bladder cancer is the sixth most common malignancy in the United States and 70% of cases are non-muscle invasive at the time of diagnosis. Effective treatment is crucial to prevent progression, which occurs in about 30% of patients. The American Urological Association (AUA) guidelines recommend treatment of non-muscle invasive bladder cancer (NMIBC) with intravesical Bacille Calmette-Guerin (BCG) and chemotherapy.
Arch Pharmacol Ther, 2022, Volume 4, Issue 1, p13-22 | DOI: 10.33696/Pharmacol.4.030
Co Authors
Saum Ghodoussipour
Rutgers Robert Wood Johnson Medical School, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
View Profile
Eric A. Singer
The Ohio State University Comprehensive Cancer Center, Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
View Profile
Ilana P. Goldberg
Tufts University School of Medicine, Boston, MA, USA, Tufts University School of Medicine, Boston, MA, USA
View Profile